End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | +1.95% | +1.23% | -31.83% |
03/06 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
30/05 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.83% | 150M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.
- Transcript : TriSalus Life Sciences, Inc., Q3 2023 Earnings Call, Nov 14, 2023